Advertisement Boehringer, Yale University to research new immunotherapy targets - Pharmaceutical Business review
Pharmaceutical Business review is using cookies

ContinueLearn More
Close

Boehringer, Yale University to research new immunotherapy targets

Boehringer Ingelheim has entered into collaboration with Yale University to research new therapeutic targets in the field of immune-modulation, which refers to a range of treatments aimed at harnessing a patient’s immune system to fight disease.

As part of the deal, the research capabilities of the two parties will be brought together to identify new immune-modulatory agents for oncology, autoimmune and respiratory disorders.

In order to advance this research, Boehringer will offer research funding for a select number of projects as well as work closely with scientists at Yale University.

Boehringer has an option to get an exclusive license for all of these programs under pre-agreed terms with Yale University.

United Technologies chair in Cancer Research and professor of Immunobiology and director of Cancer Immunology at the Yale Cancer Center, Yale University School of Medicine Dr Lieping Chen will lead this collaborative research jointly with Boehringer.

Boehringer Ingelheim senior corporate vice-president of Research and Non-clinical Development Dr Michel Pairet said: "We are very much looking forward to working closely with Dr Chen and other scientific leaders in this innovative and emerging field as part of this joint research program.

"This research collaboration affirms our commitment to the area of immune-modulation for both inflammatory diseases and oncology. In oncology, this will ideally complement our ongoing efforts in the fields of targeted therapy and cancer vaccines."